418 related articles for article (PubMed ID: 31395065)
1. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
2. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
3. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.
Shi JY; Xing Q; Duan M; Wang ZC; Yang LX; Zhao YJ; Wang XY; Liu Y; Deng M; Ding ZB; Ke AW; Zhou J; Fan J; Cao Y; Wang J; Xi R; Gao Q
Oncotarget; 2016 Jan; 7(3):2867-77. PubMed ID: 26672766
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
5. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.
Amaddeo G; Cao Q; Ladeiro Y; Imbeaud S; Nault JC; Jaoui D; Gaston Mathe Y; Laurent C; Laurent A; Bioulac-Sage P; Calderaro J; Zucman-Rossi J
Gut; 2015 May; 64(5):820-9. PubMed ID: 25021421
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan.
Lunn RM; Zhang YJ; Wang LY; Chen CJ; Lee PH; Lee CS; Tsai WY; Santella RM
Cancer Res; 1997 Aug; 57(16):3471-7. PubMed ID: 9270015
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma.
Yu M; Xu W; Jie Y; Pang J; Huang S; Cao J; Gong J; Li X; Chong Y
World J Surg Oncol; 2021 Mar; 19(1):66. PubMed ID: 33685467
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus genetic variation and TP53 R249S mutation in patients with hepatocellular carcinoma in Thailand.
Thongbai C; Sa-nguanmoo P; Kranokpiruk P; Poovorawan K; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2013; 14(6):3555-9. PubMed ID: 23886144
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma.
Xue M; Wu Y; Fan W; Guo J; Wei J; Wang H; Tan J; Wang Y; Yao W; Zhao Y; Li J
Cancer Res Treat; 2020 Jul; 52(3):925-937. PubMed ID: 32229792
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes.
Vivekanandan P; Torbenson M; Ramakrishna B
J Gastrointest Cancer; 2011 Mar; 42(1):20-5. PubMed ID: 20963515
[TBL] [Abstract][Full Text] [Related]
13. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
Katiyar S; Dash BC; Thakur V; Guptan RC; Sarin SK; Das BC
Cancer; 2000 Apr; 88(7):1565-73. PubMed ID: 10738214
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
15. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
16. Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.
Mao R; Liu J; Liu G; Jin S; Xue Q; Ma L; Fu Y; Zhao N; Xing J; Li L; Qiu Y; Lin B
Oncotarget; 2017 Apr; 8(16):26185-26199. PubMed ID: 28412734
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1.
Park US; Su JJ; Ban KC; Qin L; Lee EH; Lee YI
Gene; 2000 Jun; 251(1):73-80. PubMed ID: 10863098
[TBL] [Abstract][Full Text] [Related]
18. Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection.
Long J; Wang Y; Li M; Tong WM; Jia JD; Huang J
Oncol Rep; 2013 Jul; 30(1):119-24. PubMed ID: 23624687
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics analysis of key biomarkers and potential molecular mechanisms in hepatocellular carcinoma induced by hepatitis B virus.
Li Z; Xu J; Cui H; Song J; Chen J; Wei J
Medicine (Baltimore); 2020 May; 99(20):e20302. PubMed ID: 32443377
[TBL] [Abstract][Full Text] [Related]
20. Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet.
Hsia CC; Kleiner DE; Axiotis CA; Di Bisceglie A; Nomura AM; Stemmermann GN; Tabor E
J Natl Cancer Inst; 1992 Nov; 84(21):1638-41. PubMed ID: 1279184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
